Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
KA Schalper, ME Rodriguez-Ruiz, R Diez-Valle… - Nature medicine, 2019 - nature.com
Glioblastoma is the most common primary central nervous system malignancy and has a
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
J De Groot, M Penas-Prado, K Alfaro-Munoz… - Neuro …, 2020 - academic.oup.com
Background We sought to ascertain the immune effector function of pembrolizumab within
the glioblastoma (GBM) microenvironment during the therapeutic window. Methods In an …
the glioblastoma (GBM) microenvironment during the therapeutic window. Methods In an …
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent …
AH Lee, L Sun, AY Mochizuki, JG Reynoso… - Nature …, 2021 - nature.com
Primary brain tumors, such as glioblastoma (GBM), are remarkably resistant to
immunotherapy, even though pre-clinical models suggest effectiveness. To understand this …
immunotherapy, even though pre-clinical models suggest effectiveness. To understand this …
Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial
DA Reardon, AA Brandes, A Omuro… - JAMA …, 2020 - jamanetwork.com
Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …
Combination immunotherapy strategies for glioblastoma
Introduction Despite recent advances in treatment for a number of cancers with immune
checkpoint blockade (ICB), immunotherapy has had limited efficacy in glioblastoma (GBM) …
checkpoint blockade (ICB), immunotherapy has had limited efficacy in glioblastoma (GBM) …
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
A Omuro, G Vlahovic, M Lim, S Sahebjam… - Neuro …, 2018 - academic.oup.com
Background Immunotherapies have demonstrated efficacy across a diverse set of tumors
supporting further evaluation in glioblastoma. The objective of this study was to evaluate the …
supporting further evaluation in glioblastoma. The objective of this study was to evaluate the …
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
T Yang, Z Kong, W Ma - Human Vaccines & Immunotherapeutics, 2021 - Taylor & Francis
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Immune checkpoint inhibitors have been successful across several tumor types; however,
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10 …
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10 …
相关搜索
- recurrent glioblastoma survival benefit
- recurrent glioblastoma immunosuppressive tumor
- recurrent glioblastoma pembrolizumab in patients
- recurrent glioblastoma randomized phase
- recurrent glioblastoma associated macrophages
- recurrent glioblastoma effect of nivolumab
- recurrent glioblastoma exploratory phase
- recurrent glioblastoma ipilimumab in patients
- recurrent glioblastoma bevacizumab in patients